Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 145, Issue 10, pp 2529–2539 | Cite as

PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma

  • Yiqin Wang
  • Li Xie
  • Rong Tian
  • Yaotiao Deng
  • Wenyan Zhang
  • Liqun Zou
  • Hong Zhang
  • Jie Liu
  • Sha Zhao
  • Wenshuang Ding
  • Weiping Liu
  • Ming JiangEmail author
Original Article – Clinical Oncology

Abstract

Purpose

This study aimed to determine the potential of positron emission tomography/computed tomography (PET/CT) in replacing routine bone-marrow biopsies (BMB) in newly diagnosed extranodal natural killer/T-cell lymphoma (ENKTCL).

Methods

Newly diagnosed patients underwent PET/CT imaging and routine BMB to assess bone/bone marrow involvement (BMI). Clinical stage and treatment plan were determined, and survival was compared.

Results

In a total of 101 patients, 78 were diagnosed as stage I/II and 23 as stage III/IV without using the BMB results. No BMB-positive patients were identified in stages I/II, and therefore, the BMB results did not alter the stage and treatment choice in any patients. The sensitivity and specificity of focal skeletal PET/CT lesion(s) in assessing BMI was 100% and 92.8%, respectively, taking routine BMB as the reference standard. The overall survival (OS) and progression-free survival (PFS) of BMB-positive patients was significantly inferior (P = 0.0011 and 0.0465, respectively, in advanced-stage patients; both P < 0.0001 in all patients), and this was corroborated by the PET/CT findings (P = 0.0006 and 0.0116, respectively, in advanced-stage patients; both P < 0.0001 in all patients).

Conclusions

Based on the results, PET/CT demonstrated satisfactory predictive performance in terms of staging and prognosis in ENKTCL. BMB did not influence staging and treatment in newly diagnosed ENKTCL, and routine non-targeted BMB is not obligatory for early stage patients undergoing PET/CT. Targeted BMB is recommended to confirm BMI in advanced-stage patients.

Keywords

Extranodal natural killer/T-cell lymphoma (ENKTCL) PET/CT Bone-marrow biopsy Bone/bone-marrow involvement Prognosis 

Notes

Acknowledgements

This study has no specific funding. We are grateful to the patients in this trial and clinical staff from the pathology and nuclear medicine departments of West China Hospital for their assistance.

Author contributions

YW and MJ performed the research. MJ designed the research study. Other authors analyzed the data; YW and MJ wrote the paper.

Compliance with ethical standards

Conflict of interest

The authors declared no conflict of interest to this work.

Ethical approval

We abided by ethical standards of the institutional and/or national research committee, the Helsinki Declaration in 1964 and its later amendments or comparable ethical standards in all procedures performed in this study and all human participants involved.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. Adams HJA, Kwee TC (2015) Critical views on the prognostic potential and interpretation of bone marrow F-18-FDG PET in diffuse large B-cell lymphoma. J Nucl Med 56:163–164.  https://doi.org/10.2967/jnumed.114.148577 CrossRefPubMedGoogle Scholar
  2. Adams HJA, Kwee TC, de Keizer B, Fijnheer R, de Klerk JMH, Littooij AS, Nievelstein RAJ (2014) Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol 25:921–927.  https://doi.org/10.1093/annonc/mdt533 CrossRefPubMedGoogle Scholar
  3. Adams HJA, de Klerk JMH, Fijnheer R, Dubois SV, Nievelstein RAJ, Kwee TC (2015) Paget’s disease of the bone mimicking lymphomatous bone marrow involvement at FDG-PET. Am J Hematol 90:269–270.  https://doi.org/10.1002/ajh.23921 CrossRefPubMedGoogle Scholar
  4. Au W-Y et al (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113:3931–3937.  https://doi.org/10.1182/blood-2008-10-185256 CrossRefPubMedGoogle Scholar
  5. Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy—a review of UK data for 2004. Haematol Hematol J 91:1293–1294Google Scholar
  6. Berthet L et al (2013) In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with F-18-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 54:1244–1250.  https://doi.org/10.2967/jnumed.112.114710 CrossRefPubMedGoogle Scholar
  7. Brunetti GA et al (2011) Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol 90:1233–1235.  https://doi.org/10.1007/s00277-011-1166-7 CrossRefPubMedGoogle Scholar
  8. Cencini E et al (2014) Evaluation of the prognostic role of tissue associated macrophages (TAM) in Hodgkin lymphoma and correlation with early FDG-PET assessment. Haematologica 99:397–398Google Scholar
  9. Cerci JJ et al (2014) Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med 55:1591–1597.  https://doi.org/10.2967/jnumed.113.134486 CrossRefPubMedGoogle Scholar
  10. Cerci JJ, Fanti S, Redondo F, Gyoerke T, Carr R (2015) Critical views on the prognostic potential and interpretation of bone marrow F-18-FDG PET in diffuse large B-cell lymphoma reply. J Nucl Med 56:164.  https://doi.org/10.2967/jnumed.114.150086 CrossRefPubMedGoogle Scholar
  11. Cheng G, Chen W, Chamroonrat W, Torigian DA, Zhuang H, Alavi A (2011) Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging 38:1469–1476.  https://doi.org/10.1007/s00259-011-1815-z CrossRefPubMedGoogle Scholar
  12. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059.  https://doi.org/10.1200/jco.2013.54.8800 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Deng TX, Zhang C, Zhang X, Wu S, Xu YQ, Liu SS, Chen XH (2014) Treatment outcome of radiotherapy alone versus radiochemotherapy in IE/IIE extranodal nasal-type natural killer/T cell lymphoma: a meta-analysis. Plos One 9:e106577.  https://doi.org/10.1371/journal.pone.0106577 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Dreyling M et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105:2677–2684.  https://doi.org/10.1182/blood-2004-10-3883 CrossRefPubMedGoogle Scholar
  15. El-Galaly TC et al (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30:4508–4514.  https://doi.org/10.1200/jco.2012.42.4036 CrossRefPubMedGoogle Scholar
  16. Fowler N, Asatiani E, Cheson B (2008) Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. Leuk Lymphoma 49:156–158.  https://doi.org/10.1080/10428190701732846 CrossRefPubMedGoogle Scholar
  17. Fujiwara H et al (2011) The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma. Eur J Haematol 87:123–129.  https://doi.org/10.1111/j.1600-0609.2011.01645.x CrossRefPubMedGoogle Scholar
  18. Harris NL et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849CrossRefPubMedGoogle Scholar
  19. Heron DE, Andrade RS, Beriwal S, Smith RP (2008) PET-CT in radiation oncology—the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol Cancer Clin Trials 31:352–362.  https://doi.org/10.1097/coc.0b013e318162f150 CrossRefGoogle Scholar
  20. Hopkins E, Devenish G, Evans G, Leopold G, Rees J, Parry-Jones N (2014) Subcutaneous seeding of ‘double hit’ diffuse large B-cell lymphoma from staging bone marrow biopsy. Br J Haematol 166:635.  https://doi.org/10.1111/bjh.12979 CrossRefPubMedGoogle Scholar
  21. Hu C (2016) Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type. Nucl Med Commun Nucl Med Commun 37:446–452CrossRefPubMedGoogle Scholar
  22. Hutchings M et al (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica Hematol J 91:482–489Google Scholar
  23. Jiang M et al (2017) A phase II prospective study of the “Sandwich” protocol, l-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Oncotarget 8:50155–50163.  https://doi.org/10.18632/oncotarget.16334 CrossRefPubMedPubMedCentralGoogle Scholar
  24. Karantanis D et al (2008) The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 8:94–99.  https://doi.org/10.3816/clm.2008.n.010 CrossRefPubMedGoogle Scholar
  25. Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, Carr R (2013) PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 122:61–67.  https://doi.org/10.1182/blood-2012-12-473389 CrossRefPubMedGoogle Scholar
  26. Kim SJ, Park S, Kang ES, Choi JY, Lim DH, Ko YH, Kim WS (2015) Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol 94:71–78.  https://doi.org/10.1007/s00277-014-2171-4 CrossRefPubMedGoogle Scholar
  27. Kwee TC, de Klerk JMH, Nievelstein RAJ (2011) Imaging of bone marrow involvement in lymphoma: state of the art and future directions. Sci World J 11:391–402.  https://doi.org/10.1100/tsw.2011.40 CrossRefGoogle Scholar
  28. Lee J et al (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612–618.  https://doi.org/10.1200/jco.2005.04.1384 CrossRefPubMedGoogle Scholar
  29. Li YX et al (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181–189.  https://doi.org/10.1200/jco.2005.03.2573 CrossRefPubMedGoogle Scholar
  30. Li Y-X et al (2012) Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 82:1809–1815CrossRefPubMedGoogle Scholar
  31. Liang J-H et al (2017) Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by F-18-FDG PET/CT in extra-nodal NK/T-cell lymphoma. Oncotarget 8:1737–1743.  https://doi.org/10.18632/oncotarget.13873 CrossRefPubMedGoogle Scholar
  32. Muslimani AA et al (2008) The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol Cancer Clin Trials 31:409–412.  https://doi.org/10.1097/coc.0b013e318168d90b CrossRefGoogle Scholar
  33. Oshimi K (2007) Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139:532–544.  https://doi.org/10.1111/j.1365-2141.2007.06835.x CrossRefPubMedGoogle Scholar
  34. Pak K et al (2017) Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol.  https://doi.org/10.1016/j.amjoto.2017.10.009 CrossRefPubMedGoogle Scholar
  35. Smith SD, Redman M, Dunleavy K (2015) FDG PET-CT in follicular lymphoma: a case-based evidence review Blood 125:1078–1082.  https://doi.org/10.1182/blood-2014-11-537522 CrossRefPubMedGoogle Scholar
  36. Storto G et al (2010) Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. Br J Haematol 151:195–197.  https://doi.org/10.1111/j.1365-2141.2010.08335.x CrossRefPubMedGoogle Scholar
  37. Suh C et al (2008) Prognostic value of tumor F-18-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 49:1783–1789.  https://doi.org/10.2967/jnumed.108.053355 CrossRefPubMedGoogle Scholar
  38. Wang YQ, Yang Y, Zhuo HY, Zou LQ, Jiang Y, Jiang M (2015) Trial of LVDP regimen (l-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma. Med Oncol.  https://doi.org/10.1007/s12032-014-0435-4 CrossRefPubMedPubMedCentralGoogle Scholar
  39. Wu H-B, Wang Q-S, Wang M-F, Li H-S, Zhou W-L, Ye X-H, Wang Q-Y (2010) Utility of F-18-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun 31:195–200.  https://doi.org/10.1097/mnm.0b013e32833310fa CrossRefPubMedGoogle Scholar
  40. Yang L, Liu H, Xu X-h, Wang X-f, Huang H-m, Shi W-y, Jiang S-h (2013) Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Med Oncol (Northwood, London, England) 30:720.  https://doi.org/10.1007/s12032-013-0720-7 CrossRefGoogle Scholar
  41. Yhim HY et al (2014) Prognostic significance of interim positron emission tomography scan in patients with mature T-cell and NK-cell lymphoma. Haematologica 99:699Google Scholar
  42. Yiqin W et al (2015) The promise of PET/CT-based bone marrow assessment in replacing routine bone marrow biopsy for staging and prognosis of extranodal natural killer/T-cell lymphoma. Ann Oncol 26:86CrossRefGoogle Scholar
  43. Zhou X, Lu K, Geng L, Li X, Jiang Y, Wang X (2014) Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma a systematic review and meta-analysis. Medicine.  https://doi.org/10.1097/md.0000000000000258 CrossRefPubMedPubMedCentralGoogle Scholar
  44. Zhou Z et al (2015) Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT. Ann Hematol 94:963–967.  https://doi.org/10.1007/s00277-014-2289-4 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Center of Medical Oncology, West China HospitalSichuan UniversityChengduChina
  2. 2.Department of Nuclear Medicine, West China HospitalSichuan UniversityChengduChina
  3. 3.Department of Pathology, West China HospitalSichuan UniversityChengduChina

Personalised recommendations